Date: June 11, 2019
Location: Munich, Germany
11.10 AM - 11.50 AM: Review of current CMC strategies for immune-oncology protein candidates & Case studies – Christelle Dagoneau – Catalent
Immuno oncology now represents a real therapeutic breakthrough and is still rapidly evolving. Within just a few years, immunotherapies have been approved as an important treatment option for many cancer patients.
Pharmaceutical and biotech companies face significant pressure to accelerate immuno-oncology drug candidates from discovery to clinical use. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development.